| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265265 | MC2 | Topical composition |
Sep, 2027
(3 years from now) | |
| US11638711 | MC2 | NA |
Mar, 2039
(15 years from now) | |
| US11696919 | MC2 | Topical composition |
Mar, 2039
(15 years from now) | |
Wynzora is owned by Mc2.
Wynzora contains Betamethasone Dipropionate; Calcipotriene.
Wynzora has a total of 3 drug patents out of which 0 drug patents have expired.
Wynzora was authorised for market use on 20 July, 2020.
Wynzora is available in cream;topical dosage forms.
The generics of Wynzora are possible to be released after 18 March, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form (NDF) | Jul 20, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
WYNZORA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic